Skip to Content

Investor Relations

Investor Relations

Company Overview

Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases. Monoclonal antibodies, or mAbs, are a well-established therapeutic class across many disease areas; however, they have yet to be broadly utilized for the prevention or treatment of acute bacterial and viral infections, where they hold the potential to address serious unmet medical needs. Unlike antibiotics that propagate resistance, disrupt both disease-causing and beneficial bacteria and have adverse off-target effects, mAbs have the ability to precisely bind only to an intended target, thereby avoiding these undesired consequences. Our expertise lies in applying our deep understanding of infectious disease pathogenesis paired with our ability to access some of the most advanced mAb discovery techniques and platforms available today. We have used this expertise to discover and develop novel mAbs with multiple mechanisms of action and high potency against their intended targets.
 

News Releases

November 27, 2018 at 7:00 AM EST
– Merger Expected to Create NASDAQ-listed, Late-stage Biopharmaceutical Company Focused on Rare Diseases and Cancer – – Phase 3 Clinical Trial for X4P-001, a Novel CXCR4 Antagonist, Anticipated to Start 1H 2019 – – Conference call to be held today at 8:30 AM ET – CAMBRIDGE, Mass. and WALTHAM, Mass.
November 9, 2018 at 8:00 AM EST
WALTHAM, Mass. and VIENNA, Austria , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases, today reported financial results for the third
August 13, 2018 at 8:00 AM EDT

WALTHAM, Mass. and VIENNA, Austria , Aug. 13, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases, today reported financial results for the second

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Top